Condition

Rhinovirus Infection

ClinicalTrials.gov condition label

Clinical trials3

Recruiting2

Common interventions6

Lead sponsors shown2

Clinical trials

3 shown

Trial Comparing the Safety and Efficacy of Two Different Oral VPV Doses With Placebo as Treatment for RV in Participants With COPDNCT07610395 · 2026-05-01

Using Multiomics to Define Mechanisms of Rhinovirus-induced Chronic Obstructive Pulmonary Disease Exacerbations to Develop Novel Therapies and Therapeutic TargetsNCT07112235 · 2025-10-08

RCT of Vapendavir in Patients With COPD and Human Rhinovirus/Enterovirus Upper Respiratory InfectionNCT06149494 · 2023-11-20

Common interventions

PlaceboDRUG1 PlaceboOTHER1 Rhinovirus-A16BIOLOGICAL1 VapendavirDRUG1 VPV 1000 mgDRUG1 VPV 500 mgDRUG1

Leading sponsors

Altesa Biosciences, Inc.2 Imperial College London1

Trial status mix

RECRUITING2

COMPLETED1

Phase mix

PHASE22

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.